According to the Peripheral Arterial Disease Coalition, PAD of the lower extremities affects approximately eight million people in the US, although many patients are unaware of their condition or the seriousness of it.

According to the company, the complete SE Vascular Stent System features several novel advances, including an innovative dual?deployment delivery system with a unique triaxial design. The new delivery system is made up of an inner shaft, a retractable sheath and a stabilizing sheath that reduces friction and allows the retractable sheath to move back freely.

Sean Salmon, vice president and general manager of Coronary and Peripheral, part of the CardioVascular business, at Medtronic, said: “FDA approval of the Complete SE Vascular Stent System for a peripheral indication marks a successful milestone in our PAD clinical research program.

“Following our acquisition of Invatec, this approval augments Medtronic’s offerings in a large and growing market where patients are significantly under?diagnosed and could benefit from expanded treatment options.”

Will the approval further Medtronic in CardioVascular research area?

Have your say and discuss with your peers on the InfoGrok community.

Participate by posting your comments now.